[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100645363":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":20,"responsibleParty":27,"collaborators":20,"id":31,"slug":20,"hasResults":32,"nctId":33,"briefTitle":34,"officialTitle":35,"acronym":36,"eligibilityCriteria":37,"healthyVolunteers":32,"sex":38,"minAge":39,"maxAge":40,"enrollmentInfo":41,"targetDuration":20,"studyType":44,"phases":45,"briefSummary":47,"conditions":48,"keywords":20,"overallStatus":51,"whyStopped":20,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":20},{"fullName":5,"class":6},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients who meet the inclusion criteria","EXPERIMENTAL","This is a single arm study. All enrolled patients will receive the same interventions throughout the study.",[13],"Diagnostic Test: The interventions of the study are the study of blood biomarkers and neuroimaging and neurophysiological data",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DIAGNOSTIC_TEST","The interventions of the study are the study of blood biomarkers and neuroimaging and neurophysiological data","* Blood sample collection and markers analysis\n* Brain 1.5 T MRI\n* High density EEG",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Giulia Di Lazzaro, MD, PhD, Neurologist","CONTACT","+39 3333310889","giulia.dilazzaro@policlinicogemelli.it",{"type":28,"investigatorFullName":29,"investigatorTitle":30,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"PRINCIPAL_INVESTIGATOR","Di Lazzaro Giulia","MD, PhD, Neurologist","100645363",false,"NCT07681219","LRRK2 Parkinson's Disease Fingerprint","LRRK2 Associated Parkinson's Disease: Definition of a Clinical, Molecular and Neurophysiological Fingerprint","NEU-PD","Inclusion Criteria:\n\n* age 30-80 years,\n* clinically established diagnosis of PD according to the Movement Disorders Society (MDS) diagnostic criteria,\n* Hoehn \\& Yahr (H\\&Y) stage between 1 and 3,\n* 10 patients with a LRRK2 associated parkinsonism and 10 with sporadic PD tested with a NGS panel and MLPA for PD associated genes,\n* ability to provide informed consent.\n\nExclusion Criteria:\n\n* Active or history of other neurological disorders,\n* active infectious disease or history within the previous 4 weeks,\n* continuative therapy (at least 1 week) with NSAIDs or steroids within the previous 12 weeks,\n* active malignancy, autoinflammatory or autoimmune diseases or history within the previous 3 years;\n* alcohol or drug abuse or dependence\n* any contraindication to the execution of the MRI (including claustrophobia).","ALL","30 Years","80 Years",{"count":42,"type":43},20,"ESTIMATED","INTERVENTIONAL",[46],"NA","The goal of this interventional monocentric study is to identify molecular and clinical markers of LRRK2-related Parkinson's disease through blood markers analysis and deep clinical phenotyping. Patients who meet the inclusion criteria, after signing the informed consent form will be clinically evaluated by a neurologist expert in movement disorders. Eventually, patients will undergo a blood sample collection, a brain MRI, and a high density EEG. All data will be collected using an ad hoc electronic Case Report Form (CRF) developed for the study",[49,50],"Parkinsons Disease (PD)","LRRK2","NOT_YET_RECRUITING","2026-06-26",{"date":54,"type":55},"2026-07-02","ACTUAL",{"date":57,"type":43},"2026-09-01",{"date":59,"type":43},"2029-09-01",{"name":5,"class":6}]